Rana McKay, Professor of Medicine and Urology at UC San Diego Health and Co-leader of the GU Oncology Program at Moores Cancer Center, shared key highlights from ESMO 2025 Day 3 on X:
“Excellent presentation by Paul Nguyen on EnzaRad.
Heterogenous population but N1/Stampede high risk group appears to benefit.”
“Level setting discussion by Arun Azad on PSMAddition. More questions that need to be answered.”
“Excellent discussion by Elena Castro putting Capitello trial in context.
Patients with PTEN deficient tumors do poorly. Aspire Alliance for Clinical Trials in Oncology investigating docetaxel intensification in these tumors.”
“Presenting Capitello trial. Met primary endpoint but many questions remain regarding OS, toxicity, biomarker optimization. Not ready for prime time.”
“Scott Tagawa presenting the PSMAddition study of LuPSMA in mHSPC. Met primary endpoint but still need to see OS and monitor for long term toxicity.
Excellent work by so many.”
“Incredible data from EMBARK demonstrating OS benefit of ENZA + ADT for high risk BCR.”
“A long journey with Presto! Glad to see the MFS data. No statistical difference in MFS.”
“Wonderful discussion by Nick James on EnzaRad highlighting the differences between Stampede.
Lower risk group enrolled and differential effect of ARPI in higher risk group.”
You can also read: ESMO 2025 Day 2 Highlights Not to Miss.
